1. Home
  2. SOHU vs PRTA Comparison

SOHU vs PRTA Comparison

Compare SOHU & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sohu.com Limited

SOHU

Sohu.com Limited

N/A

Current Price

$16.13

Market Cap

486.8M

Sector

Technology

ML Signal

N/A

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

N/A

Current Price

$9.79

Market Cap

482.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SOHU
PRTA
Founded
1996
2012
Country
China
Ireland
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
486.8M
482.3M
IPO Year
2018
2013

Fundamental Metrics

Financial Performance
Metric
SOHU
PRTA
Price
$16.13
$9.79
Analyst Decision
Strong Buy
Buy
Analyst Count
2
9
Target Price
$20.00
$19.00
AVG Volume (30 Days)
29.9K
383.0K
Earning Date
01-01-0001
05-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$814,000.00
Revenue This Year
$1.61
$1,111.38
Revenue Next Year
$3.78
N/A
P/E Ratio
$1.16
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.79
$4.32
52 Week High
$17.30
$14.60

Technical Indicators

Market Signals
Indicator
SOHU
PRTA
Relative Strength Index (RSI) 46.49 60.48
Support Level $15.06 $9.54
Resistance Level $16.45 $10.72
Average True Range (ATR) 0.41 0.55
MACD -0.04 0.11
Stochastic Oscillator 21.91 85.94

Price Performance

Historical Comparison
SOHU
PRTA

About SOHU Sohu.com Limited

Sohu.com Ltd provides online media, games, and search products and services on PCs and mobile devices in China. The company operates in Sohu and Changyou segments. Sohu is an online media content and services provider. Through its social features, Sohu also enables users to generate and distribute content, as well as interact with each other on a platform. Changyou is an online game developer and operator. It generates maximum revenue from the Changyou segment.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

Share on Social Networks: